Catalog No.
RHF98202
Species reactivity
Human
Host species
Mouse
Isotype
IgG1
Clonality
Monoclonal
Tested applications
ELISA: 1:10000, FCM: 1:200-1:400, IF: 1:200-1:1000, IHC: 1:200-1:1000
Target
KMT2A, Lysine N-methyltransferase 2A, Myeloid/lymphoid or mixed-lineage leukemia protein 1, Myeloid/lymphoid or mixed-lineage leukemia, HRX, N-terminal cleavage product of 320 kDa, ALL1, HTRX, p180, CXXC7, C-terminal cleavage product of 180 kDa, ALL-1, Trithorax-like protein, p320, CXXC-type zinc finger protein 7, Zinc finger protein HRX, MLL, MLL1, Histone-lysine N-methyltransferase 2A, TRX1
Concentration
1 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
Q03164
Applications
ELISA, FCM, IF, IHC
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4, 0.05% Sodium Azide.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Clone ID
R3Q76
Revumenib for Relapsed or Refractory Acute Leukemia With a KMT2A Translocation., PMID:40437770
Navigating B-ALL in the Era of Blinatumomab., PMID:40435433
Magrolimab Therapy in Conjunction with Conventional Chemotherapeutics Slows Disease Progression in Pediatric Acute Myeloid Leukemia Patient-Derived Xenograft Models., PMID:40361435
Therapeutic horizon of acute myeloid leukemia: Success, optimism, and challenges., PMID:40105906
TP53 mutations are associated with CD19- relapse and inferior outcomes after blinatumomab in adults with ALL., PMID:39820649
How I treat infant acute lymphoblastic leukemia., PMID:38905593
Extramedullary infiltration in pediatric acute myeloid leukemia: Results from the Therapeutically Applicable Research to Generate Effective Treatments (TARGET) initiative., PMID:38644612
Molecular Features of HHV8 Monoclonal Microlymphoma Associated with Kaposi Sarcoma and Multicentric Castleman Disease in an HIV-Negative Patient., PMID:38612584
Association of leukemic molecular profile with efficacy of inotuzumab ozogamicin in adults with relapsed/refractory ALL., PMID:38607410
Palbociclib and chemotherapy followed by blinatumomab consolidation to CAR-T cell therapy in KMT2A-rearranged, therapy-related acute lymphoblastic leukemia., PMID:38514796
Enhanced potency of immunotherapy against B-cell precursor acute lymphoblastic leukemia by combination of an Fc-engineered CD19 antibody and CD47 blockade., PMID:38435424
LncRNA HOTTIP regulates TLR4 promoter methylation by recruiting H3K4 methyltransferase MLL1 to affect apoptosis and inflammatory response of fibroblast-like synoviocyte in rheumatoid arthritis., PMID:38363110
Lineage switch of KMT2A-rearranged adult B-lineage acute lymphoblastic leukemia following bispecific T-cell engager and monoclonal antibody therapy., PMID:38175441
How I treat refractory and relapsed acute myeloid leukemia., PMID:37944143
Long noncoding RNA Regulating ImMune Escape regulates mixed lineage leukaemia protein-1-H3K4me3-mediated immune escape in oesophageal squamous cell carcinoma., PMID:37712124
Genetic alterations and MRD refine risk assessment for KMT2A-rearranged B-cell precursor ALL in adults: a GRAALL study., PMID:37595275
Children's Oncology Group's 2023 blueprint for research: Myeloid neoplasms., PMID:37480164
Clonal origin of KMT2A wild-type lineage-switch leukemia following CAR-T cell and blinatumomab therapy., PMID:37474833
Treating CD33-Positive de novo Acute Myeloid Leukemia in Pediatric Patients: Focus on the Clinical Value of Gemtuzumab Ozogamicin., PMID:37153641
[Anti-MDA5 antibody-positive rapidly progressive interstitial lung disease after allogeneic hematopoietic cell transplantation successfully treated with triple immunosuppressive therapy]., PMID:37121767
Blinatumomab Added to Chemotherapy in Infant Lymphoblastic Leukemia., PMID:37099340
Novel agents and regimens in acute myeloid leukemia: latest updates from 2022 ASH Annual Meeting., PMID:36869366
Decreased Jumonji Domain-Containing 3 at the Promoter Downregulates Hematopoietic Progenitor Kinase 1 Expression and Cytoactivity of T Follicular Helper Cells from Systemic Lupus Erythematosus Patients., PMID:36213329
Donor-derived diffuse large B-cell lymphoma after haploidentical stem cell transplantation for acute myeloid leukemia., PMID:36171097
The immune checkpoint ICOSLG is a relapse-predicting biomarker and therapeutic target in infant t(4;11) acute lymphoblastic leukemia., PMID:35800767
Molecular Classification and Overcoming Therapy Resistance for Acute Myeloid Leukemia with Adverse Genetic Factors., PMID:35682627
Molecular characterization and clinical outcome of B-cell precursor acute lymphoblastic leukemia with IG-MYC rearrangement., PMID:35484682
MLL1 inhibition reduces IgM levels in Waldenström macroglobulinemia., PMID:35462170
Lineage Conversion in Pediatric B-Cell Precursor Acute Leukemia under Blinatumomab Therapy., PMID:35409391
Targeted inhibitors and antibody immunotherapies: Novel therapies for paediatric leukaemia and lymphoma., PMID:35121370
Pembrolizumab Achieves a Complete Response in an NF-1 Mutated, PD-L1 Positive Malignant Peripheral Nerve Sheath Tumor: A Case Report and Review of the Benchmarks., PMID:35020691
Gemtuzumab ozogamicin in (KMT2A)-rearranged adult acute myeloid leukaemia (AML) in the UK Medical Research Council AML15 and AML16 trials., PMID:34799856
Blinatumomab Nonresponse and High-Disease Burden Are Associated With Inferior Outcomes After CD19-CAR for B-ALL., PMID:34767461
Blinatumomab for paediatric mixed phenotype acute leukaemia., PMID:34254287
Gemtuzumab Ozogamicin Improves Event-Free Survival and Reduces Relapse in Pediatric KMT2A-Rearranged AML: Results From the Phase III Children's Oncology Group Trial AAML0531., PMID:34048275
Mesothelin is a novel cell surface disease marker and potential therapeutic target in acute myeloid leukemia., PMID:33938941
Activity of blinatumomab in lymphoblastic leukemia with impaired T-cell immunity due to congenital immunodeficiency., PMID:33881461
Blinatumomab following haematopoietic stem cell transplantation - a novel approach for the treatment of acute lymphoblastic leukaemia in infants., PMID:33843056
Lineage Switch in an Infant B-Lymphoblastic Leukemia With t(1;11)(p32;q23); KMT2A/EPS15, Following Blinatumomab Therapy., PMID:33749383
Long-term follow-up of salvage therapy using a combination of inotuzumab ozogamicin and mini-hyper-CVD with or without blinatumomab in relapsed/refractory Philadelphia chromosome-negative acute lymphoblastic leukemia., PMID:33740268
Outcomes for Australian children with relapsed/refractory acute lymphoblastic leukaemia treated with blinatumomab., PMID:33638292
Acute Leukemia in Infants., PMID:33580326
Acute Myeloid Leukemia in Children: Emerging Paradigms in Genetics and New Approaches to Therapy., PMID:33439382
Reciprocal ATP5L-KMT2A gene fusion in a paediatric B lymphoblastic leukaemia/lymphoma (B-ALL) patient., PMID:32729113
T-lymphoid/myeloid mixed phenotype acute leukemia and early T-cell precursor lymphoblastic leukemia similarities with NOTCH1 mutation as a good prognostic factor., PMID:31118806
SETD2 mutations confer chemoresistance in acute myeloid leukemia partly through altered cell cycle checkpoints., PMID:30967619
The Incidence and Immunophenotypic and Genetic Features of JL1 Expressing Cells and the Therapeutic Potential of an Anti-JL1 Antibody in De Novo Pediatric Acute Leukemias., PMID:30809981
Flow cytometric predictive scoring systems for common fusions ETV6/RUNX1, BCR/ABL1, TCF3/PBX1 and rearrangements of the KMT2A gene, proposed for the initial cytogenetic approach in cases of B-acute lymphoblastic leukemia., PMID:30730614
NG2 antigen is a therapeutic target for MLL-rearranged B-cell acute lymphoblastic leukemia., PMID:30635633
For research use only. Not for human or drug use.
